An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice

Inclusion Criteria:

• Participants with a diagnosis of moderate to severe Ulcerative colitis (UC).

• Participants initiating upadacitinib at the clinician's discretion as part of theirroutine clinical care; the decision to administer upadacitinib must be made prior toand independent of recruitment into the study.

• Participants prescribed upadacitinib in accordance with the approved local label.

• Participants able to understand and communicate with the investigator and complywith the requirements of the study.

• Participants willing to continue with study documentation after cessation ofupadacitinib.

• Participants willing and able to participate in the collection of patient-reporteddata via cloud based mobile application using the provided smart device (iPhone).

Exclusion Criteria:

• Participants with any contraindication to upadacitinib.

• Participants previously exposed to upadacitinib in a clinical trial.

• Participants currently participating in interventional research (not includingnoninterventional study, postmarketing observational study (PMOS), or registryparticipation).